TY - JOUR T1 - Stability of Eosinophilic Inflammation in COPD Bronchial Biopsies JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.00622-2020 SP - 2000622 AU - Andrew Higham AU - Sophie Leow-Dyke AU - Natalie Jackson AU - Dave Singh Y1 - 2020/01/01 UR - http://erj.ersjournals.com/content/early/2020/05/13/13993003.00622-2020.abstract N2 - Blood eosinophil counts (BEC) predict the response to inhaled corticosteroids (ICS) in COPD patients with increased exacerbation risk [1, 2]. Studies have shown an association between BEC and both sputum and lung tissue eosinophil counts in COPD patients [3, 4], supporting BEC as a biomarker that reflects the degree of eosinophilic lung inflammation. While the long-term stability of BEC in COPD patients has been studied [5–7], the stability of eosinophilic airway inflammation in COPD patients is less clear. Good stability of COPD sputum eosinophil counts up to 3 months has been reported [8, 9], but similar analysis using sub-mucosal eosinophil counts (SMEC) are lacking.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. Higham reports personal fees from Chiesi, outside the submitted work.Conflict of interest: Dr. Leow-Dyke has nothing to disclose.Conflict of interest: Miss Jackson has nothing to disclose.Conflict of interest: Dr. Singh reports personal fees from AstraZeneca, personal fees from Boehringer Ingelheim, personal fees from Chiesi, personal fees from Cipla, personal fees from Genentech, personal fees from GlaxoSmithKline, personal fees from Glenmark, personal fees from Gossamerbio, personal fees from Menarini, personal fees from Mundipharma, personal fees from Novartis, personal fees from Peptinnovate, personal fees from Pfizer, personal fees from Pulmatrix, personal fees from Theravance, personal fees from Verona, outside the submitted work. ER -